Champions TumorGrafts Can Improve Therapeutic Response

Introducing an in vivo tumor model for predicting therapeutic efficacy1. A Personalized TumorGraft is Champions Oncology’s innovative platform for implanting a piece of your patient’s live tumor directly into an immune-deficient mouse.

  • This revolutionary method preserves the characteristics of the tumor, as if it were growing in the patient, with all of its different cells and supportive stroma, inside a living environment. (Click here for a comparison of TumorGrafts to traditional xenografts.) 
  • Over time, the tumor will be expanded and implanted into additional mice.
  • Champions will then test multiple  anti-cancer drug regimens on these mice to identify which one(s) may be most effective at either shrinking or inhibiting the growth of your patient’s tumor.

Champions has conducted studies that have shown that a treatment that either shrinks the tumor or largely inhibits the growth of the tumor implanted into mice has a high likelihood of also working against the tumor in the patient’s body1,2,3.

Your patient benefits because these treatments are tested on a live sample of the entire tumor, rather than on the patient — so you might lessen the risk of needless side effects for treatments that might not work on them.

References:

  1. Hidalgo M et al. Activity of gemcitabine in direct patient derived xenografts predicts clinical outcome: validation of an in vivo model for drug development. J Clin Oncol 27:15s, 2009 (suppl; abstr 4528)
  2. Hidalgo M et al. A Pilot Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Mol Cancer Ther August 2011 10:1311-1316
  3. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006;12:4652-4661.
  4. Champions data on file.